Skip to main content

Ornit Chiba-Falek

Professor in Neurology
Neurology, Behavioral Neurology
Duke Box 2900, Durham, NC 27710
311 Research Drive, Bryan Research Building, Room 201A, Durham, NC 27710

Selected Grants


Summer Scholars in Genome Sciences & Medicine

Inst. Training Prgm or CMESignificant Contributor · Awarded by National Institutes of Health · 2017 - 2026

Sex-dependent genetic landscape of late-onset Alzheimer's disease

ResearchPrincipal Investigator · Awarded by Alzheimer's Association · 2022 - 2025

Mechanisms of mitochondrial genome integrity in familial and idiopathic Parkinson's disease

ResearchCo Investigator · Awarded by National Institutes of Health · 2020 - 2025

Untangling the diversity in the genetic architecture of late-onset Alzheimer's disease using single cell multi-omics

ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2022 - 2025

Lewy body neuropathologies and SNCA gene: variants expression and splicing

ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2020 - 2025

Summer Scholars in Genome Sciences & Medicine

Inst. Training Prgm or CMESignificant Contributor · Awarded by National Institutes of Health · 2017 - 2026

Sex-dependent genetic landscape of late-onset Alzheimer's disease

ResearchPrincipal Investigator · Awarded by Alzheimer's Association · 2022 - 2025

Mechanisms of mitochondrial genome integrity in familial and idiopathic Parkinson's disease

ResearchCo Investigator · Awarded by National Institutes of Health · 2020 - 2025

Untangling the diversity in the genetic architecture of late-onset Alzheimer's disease using single cell multi-omics

ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2022 - 2025

Lewy body neuropathologies and SNCA gene: variants expression and splicing

ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2020 - 2025

A novel producer cell line for more efficient manufacturing of viral vector systems

ResearchPrincipal Investigator · Awarded by CLAIRIgene · 2023 - 2025

Duke Creating ADRD Researchers for the Next Generation - Stimulating Access to Research in Residency Program (CARiNG-StARR)"

Inst. Training Prgm or CMEPreceptor · Awarded by National Institutes of Health · 2020 - 2024

Duke CTSA (TL1) Year 5

Inst. Training Prgm or CMEMentor · Awarded by National Institutes of Health · 2018 - 2024

A novel gene-therapy strategy for Parkinson's disease (PD): Epigenome editing mediated-regulation of SNCA expression

ResearchPrincipal Investigator · Awarded by Michael J. Fox Foundation for Parkinson's Research · 2022 - 2024

Seelos SRA-PD Model Vectors Generation for CRO SLS004

ResearchCo-Principal Investigator · Awarded by Seelos Therapeutics · 2022 - 2024

Deciphering the regulation of gene expression in the etiology of LOAD

ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2017 - 2023

Developing Novel Medicines to Treat Dystonia

ResearchCollaborator · Awarded by Department of Defense · 2019 - 2023

Proteomic Determination of APOE4-induced Neuroinflammation in the Pathogenesis of Alzheimer's Disease

ResearchConsultant · Awarded by Ruth K. Broad Biomedical Research Foundation · 2020 - 2022

Hepara sulfate proteoglycan in Alzheimer's disease

ResearchPrincipal Investigator · Awarded by University of South Florida · 2019 - 2021

Role of the TOMM40 poly-T variant in the pathogenesis of Alzheimer's disease

ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2013 - 2020

Lewy body neuropathologies and SNCA gene: variants expression and splicing

ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2013 - 2020

ApoE, Alzheimers and Aging: discover the tripleA in iPSC-derived models

FellowshipPrincipal Investigator · Awarded by Alzheimer's Association · 2018 - 2019

Immunosuppression in humans with AD

ResearchCo Investigator · Awarded by National Institutes of Health · 2016 - 2018

External Relationships


  • CLAIRIgene
  • Seelos Therapeutics

This faculty member (or a member of their immediate family) has reported outside activities with the companies, institutions, or organizations listed above. This information is available to institutional leadership and, when appropriate, management plans are in place to address potential conflicts of interest.